RxDoctor Payments Data

Rose Adonis, NP

Psychiatric/Mental Health · Orlando, FLNPI 1760169619

Payments from drug & device makers

$2,767in general payments, 2019–2025

Across 84 payments — averaging $32.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$749
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$436
  • Alkermes, Inc.$377
  • AbbVie$254
  • Teva Pharmaceuticals USA, Inc.$214
  • Axsome Therapeutics, Inc.$211
  • plus $526 from 8 others

What the payments were for

  • Food & beverage$2,767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,767 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$3,237
Medicare patients
16
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl50$77,573
Abilify MaintenaAripiprazole20$56,215
LybalviOlanzapine/Samidorphan Malate16$27,172
SpravatoEsketamine Hcl13$15,162
Aripiprazole120$7,935
Lurasidone Hcl28$4,444
Quetiapine Fumarate109$1,919
Buspirone Hcl156$1,672
Trazodone Hcl296$1,571
Sertraline Hcl258$1,540
Hydroxyzine Pamoate160$1,415
Mirtazapine87$1,284
Fluoxetine Hcl187$1,233
Olanzapine24$1,016
Risperidone95$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$254$77,57350 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$69$56,21520 claims
Alkermes, Inc.Lybalvi$377$27,17216 claims
Johnson & JohnsonSpravato$749$15,16213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →